Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus

Atherosclerosis

Volumn 189, Issue 1, 2006, Pages 149-156

  Wootton, P T E ^a   Stephens, J W ^a,b   Hurel, S J ^b   Durand, H ^c   Cooper, J ^a   Ninio, E ^c   Humphries, S E ^a   Talmud, P J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c INSERM   (France)

Author keywords

Diabetes; Lp PLA2; Metabolic syndrome; Oxidised LDL; PAFAH

Indexed keywords

ENZYME; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2G7 A379 V; STATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUCASIAN; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SCORING SYSTEM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS; DNA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHOLIPASES A; PHOSPHOLIPASES A2; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTORS;

EID: 33748956080     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.12.009     Document Type: Article

References (35)

1. Six D.A., and Dennis E.A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488 (2000) 1-19
2. Korth R., Bidault J., Palmantier R., Benveniste J., and Ninio E. Human platelets release a paf-acether: acetylhydrolase similar to that in plasma. Lipids 28 (1993) 193-199
3. Stafforini D.M., Elstad M.R., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 265 (1990) 9682-9687
4. Tjoelker L.W., Wilder C., Eberhardt C., et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374 (1995) 549-553
5. Stafforini D.M., McIntyre T.M., Carter M.E., and Prescott S.M. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262 (1987) 4215-4222
6. Marathe G.K., Prescott S.M., Zimmerman G.A., and McIntyre T.M. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med 11 (2001) 139-142
7. Blank M.L., Hall M.N., Cress E.A., and Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun 113 (1983) 666-671
8. Macphee C.H., Moores K.E., Boyd H.F., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338 Pt 2 (1999) 479-487
9. Stafforini D.M., Tjoelker L.W., McCormick S.P., et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 274 (1999) 7018-7024
10. Karabina S.A., Elisaf M., Bairaktari E., et al. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 27 (1997) 595-602
11. Hakkinen T., Luoma J.S., Hiltunen M.O., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19 (1999) 2909-2917
12. Carpenter K.L., Dennis I.F., Challis I.R., et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 505 (2001) 357-363
13. Quarck R., De Geest B., Stengel D., et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103 (2001) 2495-2500
14. Noto H., Hara M., Karasawa K., et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins. conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol (2003)
15. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 109 (2004) 837-842
16. Blake G.J., Dada N., Fox J.C., Manson J.E., and Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
17. Blankenberg S., Stengel D., Rupprecht H.J., et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44 (2003) 1381-1386
18. Packard C.J., O'Reilly D.S., Caslake M.J., et al., West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 343 (2000) 1148-1155
19. Yamada Y., Ichihara S., Fujimura T., and Yokota M. Identification of the G994 → T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 47 (1998) 177-181
20. Kruse S., Mao X.Q., Heinzmann A., et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 66 (2000) 1522-1530
21. Abuzeid A.M., Hawe E., Humphries S.E., and Talmud P.J. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 168 (2003) 283-288
22. Ninio E., Tregouet D., Carrier J.L., et al. Platelet-activating factor-acetylhydrolase (PAF-AH) and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 13 (2004) 1341-1351
23. Dhamrait S.S., Stephens J.W., Cooper J.A., et al. Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J 25 (2004) 468-475
24. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab Med 15 (1998) 539-553
25. Stafforini D.M., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Platelet-activating factor acetylhydrolases. J Biol Chem 272 (1997) 17895-17898
26. Stevens R.J., Kothari V., Adler A.I., and Stratton I.M. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101 (2001) 671-679
27. Scheffer P.G., Bos G., Volwater H.G., et al. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients. Diab Med 20 (2003) 563-567
28. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
29. Schaefer E.J., McNamara J.R., Asztalos B.F., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A(2) in patients with coronary heart disease versus control subjects. Am J Cardiol 95 (2005) 1025-1032
30. Rizos E., Tambaki A.P., Gazi I., Tselepis A.D., and Elisaf M. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 203-209
31. Lusis A.J., Mar R., and Pajukanta P. Genetics of atherosclerosis. Annu Rev Genom Hum Genet 5 (2004) 189-218
32. Song S.H., and Brown P.M. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diab Med 21 (2004) 238-245
33. Lee C., Sigari F., Segrado T., et al. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol 19 (1999) 1437-1446
34. Karasawa K., Harada A., Satoh N., Inoue K., and Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42 (2003) 93-114
35. Minelli C., Thompson J.R., Tobin M.D., and Abrams K.R. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am J Epidemiol 160 (2004) 445-452